Antiplatelet therapy aims to reduce the risk of thrombotic events while maintaining
hemostasis. A promising current approach is the inhibition of platelet glycoprotein GPVI …

Thrombus formation in hemostasis or thrombotic disease is initiated by adhesion of
circulating platelets to damaged blood vessel walls. Exposed subendothelial collagen …

Glycoprotein VI (GPVI) mediates binding of platelets to subendothelial collagen during acute
arterial thrombosis. GPVI interactions with the activated atherosclerotic vascular …

Glycoprotein VI is a type I membrane protein identified as a key platelet receptor for
collagen. In vitro binding of the GPVI receptor with collagen leads to activation and ultimately …

The treatment of acute coronary syndromes has been considerably improved in recent years
with the introduction of highly efficient antiplatelet drugs. However, there are still significant …

Collagen activates platelets by transducing signals through glycoprotein VI (GPVI). It is not
clear whether collagen can directly activate fibrinogen receptors on the adherent platelets …

Glycoprotein VI (GPVI) is a platelet-specific receptor for collagen and fibrin, regulating
important platelet functions such as platelet adhesion and thrombus growth. Although the …

Abstract Background and Aims Glycoprotein VI (GPVI) is a platelet collagen/fibrin (ogen)
receptor and an emerging pharmacological target for the treatment of thrombotic and …

GPVI belongs to the immunoglobulin superfamily. It is specifically expressed on platelets
and megakaryocytes. Since GPVI-deficient patients suffer from a very mild bleeding …

At sites of vascular injury, platelet adhesion, activation and aggregation occurs on exposed
subendothelial collagens and contributes to hemostasis but also to occlusion of diseased …